Abstract
Purpose: To evaluate the role of9-aminocamptothecin (9-AC), a syntheticcamptothecin analog, in advanced cutaneousT-cell lymphoma (CTCL). Methods: Eligible patientshad stage IIB-IV CTCL. 9-AC was infused over 72 h at adose of 1,100 μg/m2 per day (approximately46 μg/m2/h) every 2 weeks, withgranulocyte-colony stimulating factor(G-CSF) support. Results: Twelve patients received atotal of 30 cycles of 9-AC. Nine patients hadstage IV disease, 5 patients hadcirculating Sezary cells, and 2 patientshad evidence of tranformation to alarge cell lymphoma. Most of the patientswere heavily pretreated: 10 had receivedprior chemotherapy (83%), 5 of whom hadreceived 2 or more prior regimens,including a patient who had receivedhigh-dose chemotherapy, and 7 hadpreviously received total-skin electronbeam therapy. The study was prematurelyterminated due to substantial toxicity. Sixpatients (50%) developed an indwellingcentral venous catheter-related infection,5 during a period of neutropenia. Threepatients died due to sepsis 4-8 weeks aftertheir last 9-AC treatment. Two of thesepatients had a previous history ofbacterial sepsis. Four patients (33%)developed grade IV thrombocytopenia. Twopartial responses were observed (responserate 17%), but the duration of responsewas brief, 4-8 weeks. Conclusion: 9-AC at thisschedule and route of administration had activity but resultedin an unacceptable rate of complicatedneutropenia and septic deaths in heavilypretreated patients with advanced CTCL whoare susceptible to catheter-relatedinfections.
Similar content being viewed by others
REFERENCES
Zackheim HS, Amin S, Kashani-Sabet M, McMillan A: Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients. J Am Acad Dermatol 40(3): 418–425, 1999
Bunn PA, Jr., Hoffman SJ, Norris D, Golitz LE, Aeling JL: Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome). Ann Intern Med 121(8): 592–602, 1994
Rosen ST, Foss FM: Chemotherapy for mycosis fungoides and the Sezary syndrome. Hematol Oncol Clin North Am 9(5): 1109–1116, 1995
Kaye FJ, Bunn PA, Jr., Steinberg SM, Stocker JL, Ihde DC, Fischmann AB, Glatstein E, Schechter GP, Phelps RM, Foss FM, Parlette HL, Anderson MJ, Sausville EA: A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 321(26): 1784–1790, 1989
Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R, Potmesil M: DNA topoisomerase I–targeted chemotherapy of human colon cancer in xenografts. Science 246(4933): 1046–1048, 1989
Burris HA, Hanauske AR, Johnson RK, Marshall MH, Kuhn JG, Hilsenbeck SG, Von Hoff DD: Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colonyforming units in vitro. J Natl Cancer Inst 84(23): 1816–1820, 1992
Houghton PJ, Cheshire PJ, Myers L, Stewart CF, Synold TW, Houghton JA: Evaluation of 9-dimethylaminomethyl-10-hydroxycamptotheci n against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol 31(3): 229–239, 1992
Houghton PJ, Cheshire PJ, Hallman JC, Bissery MC, Mathieu-Boue A, Houghton JA: Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. Cancer Res 53(12): 2823–2829, 1993
Dahut W, Harold N, Takimoto C, Allegra C, Chen A, Hamilton JM, Arbuck S, Sorensen M, Grollman F, Nakashima H, Lieberman R, Liang M, Corse W, Grem J: Phase I and pharmacologic study of 9-aminocamptothecin given by 72-h infusion in adult cancer patients. J Clin Oncol 14(4): 1236–1244, 1996
Rubin E, Wood V, Bharti A, Trites D, Lynch C, Hurwitz S, Bartel S, Levy S, Rosowsky A, Toppmeyer D: A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. Clin Cancer Res 1(3): 269–276, 1995
Langevin AM, Casto DT, Thomas PJ, Weitman SD, Kretschmar C, Grier H, Pratt C, Dubowy R, Bernstein M, Blaney S, Vietti T: Phase I trial of 9-aminocamptothecin in children with refractory solid tumors: a Pediatric Oncology Group study. J Clin Oncol 16(7): 2494–2499, 1998
Vey N, Kantarjian H, Tran H, Beran M, O'Brien S, Bivins C, Giles F, Cortes J, Cheson B, Arbuck S, Estey E: Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia. Ann Oncol 10(5): 577–583, 1999
Hochster H, Liebes L, Speyer J, Sorich J, Chachoua A, Raphael B, Moskovits T, Taubes B, Friedberg A, Buckley M, Fry D, Arbuck S, Blum R, Potmesil M: Phase I and pharmacodynamic study of prolonged infusion 9-amino-camptothecin (9AC) in two formulations. Proc Am Soc Clin Oncol 16: A704, 1997
Siu LL, Oza AM, Eisenhauer EA, Firby PS, Thiessen JJ, Michael M, Wainman N, Manzo J, Feld R, Goldberg RA, Moore MJ: Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-h continuous infusion weekly times four every 5 weeks. J Clin Oncol 16(3): 1122–1130, 1998
Herben VMM, van Gijn R, Schellens JHM, Schot M, Lieverst J, Hildebrand MJX, Schoemaker NE, Porro MG, Beijnen JS, ten Bokkel Huinink WW: Phase I and Pharmacokinetic Study of a Daily Times 5 Short Intravenous Infusion Schedule of 9-Aminocamptothecin in a Colloidal Dispersion Formulation in Patients With Advanced Solid Tumors. J Clin Oncol 17: 1906, 1999
Mani S, Iyer L, Janisch L, Wang X, Fleming GF, Schilsky RL, Ratain MJ: Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071). Cancer Chemother Pharmacol 42(1): 84–87, 1998
de Jonge MJA, Punt CJA, Gelderblom AH, Loos WJ, van Beurden V, Planting AST, van der Burg MEL, van Maanen LWGM, Dallaire BK, Verweij J, Wagener DJT, Sparreboom A: Phase I and Pharmacologic Study of Oral (PEG-1000) 9-Aminocamptothecin in Adult Patients With Solid Tumors. J Clin Oncol 17(7): 2219, 1999
Vokes EE, Ansari RH, Masters GA, Hoffmann PC, Klepsch A, Ratain MJ, Sciortino DF, Lad TE, Krauss S, Fishkin PA, Golomb HM: A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer. Ann Oncol 9(10): 1085–1090, 1998
Pazdur R, Diaz-Canton E, Ballard WP, Bradof JE, Graham S, Arbuck SG, Abbruzzese JL, Winn R: Phase II trial of 9-aminocamptothecin administered as a 72-h continuous infusion in metastatic colorectal carcinoma. J Clin Oncol 15(8): 2905–2909, 1997
Pazdur R, Medgyesy DC, Winn RJ, Dakhil SR, Moore DF, Scalzo A, Hoff PM, Arbuck SG, Abbruzzese JL: Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hr continuous infusion weekly for three weeks in metastatic colorectal carcinoma. Invest New Drugs 16(4): 341–346, 1998
Grossman SA, Hochberg F, Fisher J, Chen TL, Kim L, Gregory R, Grochow LB, Piantadosi S: Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS Consortium. The New Approaches to Brain Tumor Therapy. Cancer Chemother Pharmacol 42(2): 118–126, 1998
Minami H, Lad TE, Nicholas MK, Vokes EE, Ratain MJ: Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 h in phase II studies. Clin Cancer Res 5(6): 1325–1330, 1999
Kraut EH, Balcerzak SP, O'Rourke M, Petrus J, Mayernik D: Phase II trial of 9-aminocamptothecin in patients with refractory breast cancer. Proc Am Soc Clin Oncol 16: A620, 1997
Wilson WH, Little R, Pearson D, Jaffe ES, Steinberg SM, Cheson BD, Humphrey R, Kohler DR, Elwood P: Phase II and dose-escalation with or without granulocyte colony-stimulating factor study of 9-aminocamptothecin in relapsed and refractory lymphomas [published erratum appears in J Clin Oncol;16: 2895]. J Clin Oncol 16(7): 2345–2351, 1998
Kraut EH, Balcerzak SP, Young D, Davis M, Jacobs H: A phase II study of topotecan in non-Hodgkin's lymphoma: a Ohio state phase 2 consortium study. Proc Am Soc Clin Oncol 17: A111, 1998
Ota K, Ohno R, Shirakawa S, Masaoka T, Okada K, Ohashi Y, Taguchi T: Late phase II clinical study of irinotecan hydrochloride (CPT-11) in the treatment of malignant lymphoma and acute leukemia. The CPT-11 Research Group for Hematological Malignancies. Gan To Kagaku Ryoho 21(7): 1047–1055, 1994
Preti HA, Plunkett W, Sarris AH, Younes A, Hagemeister F, Rodriguez MA, Romaguera I, McLaughlin P, Bachier C, Cabanillas F: Preliminary results of a phase II trial of topotecan in patients with relapsing lymphoma. Blood 88(suppl1)(A3268): 820a, 1995
Axelrod PI, Lorber B, Vonderheid EC: Infections complicating mycosis fungoides and Sezary syndrome. JAMA 267(10): 1354–1358, 1992
Akpek G, Koh HK, Bogen S, O'Hara C, Foss FM: Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma. Cancer 86(7): 1368–1376, 1999
Fierro MT, Quaglino P, Savoia P, Verrone A, Bernengo MG: Systemic polychemotherapy in the treatment of primary cutaneous lymphomas: a clinical follow-up study of 81 patients treated with COP or CHOP. Leuk Lymphoma 31(5–6): 583–588, 1998
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Argiris, A., Heald, P., Kuzel, T. et al. Phase II Trial of 9-Aminocamptothecin as a 72-h Infusion in Cutaneous T-Cell Lymphoma. Invest New Drugs 19, 321–326 (2001). https://doi.org/10.1023/A:1010613912335
Issue Date:
DOI: https://doi.org/10.1023/A:1010613912335